Alterity Therapeutics Ltd ADR (ATHE)

$3.45 -0.05 (-1.43%)
Market Cap 31.03M
Revenue (ttm) 0.00
Net Income (ttm) -7.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,400
Avg Vol 12,006
Day's Range N/A - N/A
Shares Out 8.87M
Stochastic %K 37%
Beta 0.10
Analysts Strong Sell
Price Target $11.00

Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9349 4906
Fax: 61 3 9349 4906
Address:
350 Collins Street, Suite 4 Level 14, Melbourne, Australia
GA09
GA09 Mar. 19 at 1:45 PM
$ATHE They are issuing 150M shares. Are we getting further diluted? Not sure I understand the Australian part of accounting. I know CEO has stated (multiple times) they have broadened their discussions with pharma companies who have shown interest in ATHE-434. I guess a partnership will probably happen after EO2 meeting with the FDA and design on the Phase 3 trial. Any thoughts any one?
1 · Reply
stckmuncher
stckmuncher Mar. 19 at 9:01 AM
$ATHE SIPPIN MARGARITAS ON THE BEACH SOON...
1 · Reply
stckmuncher
stckmuncher Mar. 19 at 9:00 AM
$ATHE ARE YOU AFRAID OF MONEY? DA FUCK........
0 · Reply
stckmuncher
stckmuncher Mar. 19 at 8:59 AM
$ATHE YOUR ONLY REGRET WILL BE NOT BUYING MORE SHARES.
0 · Reply
stckmuncher
stckmuncher Mar. 19 at 8:58 AM
$ATHE WE DONT FUCK AROUND WHEN IT COMES TO ATHE.
0 · Reply
stckmuncher
stckmuncher Mar. 19 at 8:58 AM
$ATHE ONE TEAM, BULLS ONLY!!
0 · Reply
stckmuncher
stckmuncher Mar. 19 at 8:57 AM
$ATHE QUIT YOUR BITCHIN!
0 · Reply
stckmuncher
stckmuncher Mar. 17 at 12:16 AM
$MIR $ATHE
0 · Reply
stckmuncher
stckmuncher Mar. 17 at 12:15 AM
$ATHE BUY BITCHES!!!!!!!$ATHE BUY BITCHES!!!!!!!$ATHE BUY BITCHES!!!!!!!$ATHE BUY BITCHES!!!!!!!$ATHE BUY BITCHES!!!!!!!$ATHE BUY BITCHES!!!!!!!
0 · Reply
Misterx69
Misterx69 Mar. 16 at 8:56 PM
$ATHE
0 · Reply
Latest News on ATHE
Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit

Mar 9, 2026, 7:25 AM EDT - 10 days ago

Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit

ATHE

Alterity Therapeutics Announces Appointment Of Daniel Claassen As Chief Medical Advisor

2026-03-04T12:58:34.000Z - 15 days ago

Alterity Therapeutics Announces Appointment Of Daniel Claassen As Chief Medical Advisor

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

Mar 2, 2026, 7:25 AM EST - 17 days ago

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

ATHE

Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

Jan 30, 2026, 7:25 AM EST - 6 weeks ago

Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

ATHE

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

Nov 12, 2025, 7:25 AM EST - 4 months ago

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

ATHE

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

Oct 31, 2025, 7:25 AM EDT - 4 months ago

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

ATHE

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Oct 9, 2025, 7:25 AM EDT - 5 months ago

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders

ATHE

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Oct 2, 2025, 7:35 AM EDT - 6 months ago

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders

ATHE

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

Sep 8, 2025, 7:35 AM EDT - 6 months ago

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

ATHE

Alterity Therapeutics to Present at the Biotech Showcase

Sep 2, 2025, 7:25 AM EDT - 7 months ago

Alterity Therapeutics to Present at the Biotech Showcase

ATHE

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

Jul 30, 2025, 7:25 AM EDT - 8 months ago

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

ATHE

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

Jul 28, 2025, 7:25 AM EDT - 8 months ago

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

ATHE

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

Jul 24, 2025, 7:25 AM EDT - 8 months ago

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

ATHE

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

Jun 23, 2025, 7:25 AM EDT - 9 months ago

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

ATHE

Alterity Therapeutics Prominently Featured at the International MSA Congress

May 12, 2025, 7:35 AM EDT - 11 months ago

Alterity Therapeutics Prominently Featured at the International MSA Congress

ATHE

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

May 7, 2025, 8:16 AM EDT - 11 months ago

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

ATHE

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

May 5, 2025, 7:35 AM EDT - 11 months ago

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

ATHE

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

Apr 30, 2025, 7:35 AM EDT - 11 months ago

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

ATHE

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Apr 28, 2025, 7:35 AM EDT - 11 months ago

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

ATHE

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Apr 10, 2025, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

ATHE

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Mar 27, 2025, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

ATHE

Alterity Therapeutics Raises A$40.0 million in Placement

Feb 10, 2025, 7:25 AM EST - 1 year ago

Alterity Therapeutics Raises A$40.0 million in Placement

ATHE

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Jan 30, 2025, 7:35 AM EST - 1 year ago

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

ATHE

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Jan 24, 2025, 7:35 AM EST - 1 year ago

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

ATHE

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Jan 9, 2025, 7:25 AM EST - 1 year ago

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

ATHE

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Dec 4, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

ATHE

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Nov 19, 2024, 7:25 AM EST - 1 year ago

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

ATHE

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Nov 12, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

ATHE

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Nov 6, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

ATHE

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Oct 31, 2024, 7:35 AM EDT - 1 year ago

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

ATHE

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Oct 14, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

ATHE

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Oct 11, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

ATHE

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Oct 2, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

ATHE

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Sep 30, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

ATHE

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Sep 23, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

ATHE

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Jul 31, 2024, 7:35 AM EDT - 1 year ago

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

ATHE

Alterity Therapeutics to Present at MST Financial Webinar

Jul 24, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Present at MST Financial Webinar

ATHE

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jul 17, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

ATHE

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jul 17, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

ATHE

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' Webinar

Jun 12, 2024, 7:22 PM EDT - 1 year ago

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' Webinar

ATHE

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

May 29, 2024, 7:21 PM EDT - 1 year ago

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

ATHE

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

May 8, 2024, 7:25 AM EDT - 2 years ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

ATHE

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

Apr 30, 2024, 7:25 AM EDT - 2 years ago

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

ATHE

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia

Apr 29, 2024, 7:25 AM EDT - 2 years ago

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia

ATHE

Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Apr 17, 2024, 7:25 AM EDT - 2 years ago

Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

ATHE

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

Apr 10, 2024, 7:25 AM EDT - 2 years ago

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

ATHE

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

Mar 26, 2024, 10:25 AM EDT - 2 years ago

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

ATHE

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

Feb 20, 2024, 10:25 AM EST - 2 years ago

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

ATHE

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Feb 6, 2024, 7:25 AM EST - 2 years ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

ATHE

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

Jan 29, 2024, 7:24 AM EST - 2 years ago

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

ATHE

Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

Dec 21, 2023, 12:30 AM EST - 2 years ago

Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

GA09
GA09 Mar. 19 at 1:45 PM
$ATHE They are issuing 150M shares. Are we getting further diluted? Not sure I understand the Australian part of accounting. I know CEO has stated (multiple times) they have broadened their discussions with pharma companies who have shown interest in ATHE-434. I guess a partnership will probably happen after EO2 meeting with the FDA and design on the Phase 3 trial. Any thoughts any one?
1 · Reply
stckmuncher
stckmuncher Mar. 19 at 9:01 AM
$ATHE SIPPIN MARGARITAS ON THE BEACH SOON...
1 · Reply
stckmuncher
stckmuncher Mar. 19 at 9:00 AM
$ATHE ARE YOU AFRAID OF MONEY? DA FUCK........
0 · Reply
stckmuncher
stckmuncher Mar. 19 at 8:59 AM
$ATHE YOUR ONLY REGRET WILL BE NOT BUYING MORE SHARES.
0 · Reply
stckmuncher
stckmuncher Mar. 19 at 8:58 AM
$ATHE WE DONT FUCK AROUND WHEN IT COMES TO ATHE.
0 · Reply
stckmuncher
stckmuncher Mar. 19 at 8:58 AM
$ATHE ONE TEAM, BULLS ONLY!!
0 · Reply
stckmuncher
stckmuncher Mar. 19 at 8:57 AM
$ATHE QUIT YOUR BITCHIN!
0 · Reply
stckmuncher
stckmuncher Mar. 17 at 12:16 AM
$MIR $ATHE
0 · Reply
stckmuncher
stckmuncher Mar. 17 at 12:15 AM
$ATHE BUY BITCHES!!!!!!!$ATHE BUY BITCHES!!!!!!!$ATHE BUY BITCHES!!!!!!!$ATHE BUY BITCHES!!!!!!!$ATHE BUY BITCHES!!!!!!!$ATHE BUY BITCHES!!!!!!!
0 · Reply
Misterx69
Misterx69 Mar. 16 at 8:56 PM
$ATHE
0 · Reply
stckmuncher
stckmuncher Mar. 16 at 1:24 PM
$ATHE 🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙🆙
0 · Reply
stckmuncher
stckmuncher Mar. 15 at 11:39 PM
$ATHE 🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨
0 · Reply
stckmuncher
stckmuncher Mar. 15 at 11:38 PM
$ATHE 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀
0 · Reply
stckmuncher
stckmuncher Mar. 15 at 11:36 PM
$ATHE WE KNOW WAZ GOOD.
0 · Reply
stckmuncher
stckmuncher Mar. 15 at 11:36 PM
$ATHE QUIT COMPLAINING AND BUY!
0 · Reply
stckmuncher
stckmuncher Mar. 15 at 11:36 PM
$ATHE PUT UP OR SHUT UP!!
0 · Reply
stckmuncher
stckmuncher Mar. 15 at 7:17 PM
$ATHE CHANGE STARTS WITH US!
0 · Reply
RobbyAxelrod1
RobbyAxelrod1 Mar. 11 at 6:49 PM
$ATHE
0 · Reply
stckmuncher
stckmuncher Mar. 11 at 3:21 AM
$ATHE LFG FOLKS!!
1 · Reply
stckmuncher
stckmuncher Mar. 11 at 3:21 AM
$ATHE WOOOOOHOOOOOOOO!1
0 · Reply
stckmuncher
stckmuncher Mar. 11 at 3:20 AM
$ATHE PREPARE YOUR BANK ACCOUNT FOR AN INFLUX OF CASH BABY!
0 · Reply
stckmuncher
stckmuncher Mar. 11 at 3:18 AM
$ATHE Thinking $65 but out price but we shall see…
0 · Reply